Rare but Serious: Ibrutinib Induced Liver Failure

Rare but Serious: Ibrutinib Induced Liver Failure

Bibliographic Details
Main Authors:	Fleur S. Kleijwegt, Afnan Abdul Roda, José Rolvink, Arnon P. Kater, Marie José Kersten, Josephine M.I. Vos
Format:	Article
Language:	English
Published:	Wolters Kluwer 2019-12-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000307

Similar Items

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Electrocardiographic Changes Associated With Ibrutinib Exposure
by: Michael G. Fradley MD, et al.
Published: (2020-06-01)

Three years of ibrutinib in CLL
by: Forconi, Francesco
Published: (2015)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Ibrutinib: A narrative drug review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

Invasive Aspergillosis in Patients Treated With Ibrutinib
by: Moritz Fürstenau, et al.
Published: (2020-04-01)

Profound Sinoatrial Arrest Associated with Ibrutinib
by: Kanupriya Mathur, et al.
Published: (2017-01-01)

Rhythm and Conduction Disorders in Patients Receiving Ibrutinib
by: EI Emelina, et al.
Published: (2019-03-01)

Ibrutinib-associated pityriasis rosea–like rash
by: Carole Bitar, MD, et al.
Published: (2018-01-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia
by: EA Nikitin, et al.
Published: (2017-07-01)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
by: Suzanne Maynard, et al.
Published: (2021-04-01)

Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy
by: Jennifer L. Miatech, et al.
Published: (2020-01-01)

Multifocal periungual granulation tissue related to ibrutinib therapy
by: Aatman Shah, MD, et al.
Published: (2020-02-01)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01)

Inhibition of effector B cells by ibrutinib in systemic sclerosis
by: Jakob Einhaus, et al.
Published: (2020-03-01)

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis
by: Ciuculete Denisa-Corina, et al.
Published: (2021-09-01)

Approaches to the prevention and therapy of ibrutinib-associated bleeding in adult patients
by: E. V. Volchkov, et al.
Published: (2018-10-01)

Ibrutinib-induced acute kidney injury via interstitial nephritis
by: Csilla Markóth, et al.
Published: (2021-01-01)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
by: Chao Xue, et al.
Published: (2020-09-01)

Safety and efficacy of ibrutinib in a patient with severe renal impairment
by: Kalman Filanovsky, et al.
Published: (2017-09-01)

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
by: Andrea Aiello, et al.
Published: (2017-01-01)

Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
by: EI Emelina, et al.
Published: (2019-09-01)

Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics)
by: Anna Sarcon MD, et al.
Published: (2016-05-01)

Ibrutinib is not an effective drug in primografts of TCF3-PBX1
by: Cesca van de Ven, et al.
Published: (2020-10-01)

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas
by: Bhawana George, et al.
Published: (2020-05-01)

Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases
by: Zaid H. Tafesh, et al.
Published: (2019-08-01)

A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib
by: Daniel S. O’Neil, et al.
Published: (2018-01-01)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
by: Denlinger NM, et al.
Published: (2018-03-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01)

Imbruvica (Ibrutinib) induced subcutaneous hematoma: A case report
by: Chinmay Jani, et al.
Published: (2021-03-01)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
by: Natalia Timofeeva, et al.
Published: (2021-04-01)

Anti-Tumorigenic and Immunomodulatory Effects of Ibrutinib Against Hepatocellular Carcinoma
by: Elkholy, Khadija Hassan
Published: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
by: Katherine R. Sittig, et al.
Published: (2021-01-01)

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
by: Feili Chen, et al.
Published: (2020-11-01)

Graft versus host disease as a complication after liver transplantation: a rare but serious association
by: Baltasar Pérez-Saborido, et al.
Published: (2016-01-01)

A rare cause of acute liver failure- a case report
by: Sónia Bernardo, et al.
Published: (2017-12-01)